The case for & against
Bull & Bear analysis
Glaukos Corporation (NASDAQ: GKOS) is a leading company in the ophthalmology market, focusing on advanced treatments for eye diseases, particularly glaucoma and keratoconus. The firm is transitioning from a solely glaucoma-focused business to a broader ophthalmology platform, with its innovative product pipeline, including iDose TR and Epioxa, which aim to redefine patient care and improve outcomes. Positioned at the forefront of ophthalmic care, Glaukos leverages its strong clinical evidence and market penetration strategy to meet patient needs effectively.
Bull says
- ↑Record Q2 net sales of $185.6M, up 50% YoY; guidance raised to $680–$700M
- ↑IDOS-TR sales hit ~$74M in Q2; Epioxa early sales ~$11M drive adoption
- ↑12 of 14 analysts rate shares “Buy” with average target of $197
- ↑U.S. coverage reaches 85% population, boosting glaucoma and keratoconus reach
- ↑Strong growth and earnings revision factors highlight positive sentiment and momentum
- ↑High institutional ownership underpins robust capital support among hedge funds
Bear says
- ↓Earnings yield negative and profitability metrics weak, signaling operational inefficiencies
- ↓Operating expenses forecast ~$600M may weigh on cash flow and margin
- ↓Regulatory headwinds from J-code implementation could disrupt Epioxa reimbursement
- ↓Gross margins at ~85% risk erosion with rising commercial and R&D costs
- ↓Competitive trials and physician pushback on pricing may slow product adoption
- ↓Elevated leverage and volatility factors raise concerns over financial flexibility
Investment themes with GKOS
Devices and instruments for medical treatment
Services and products for aging population
Earnings Call · Q2 2025 · Mgmt. Guidance
Transcript signals
Bull points
- we believe that the largest utilization continues to be in standalone procedures and as reimbursement gets solidified, surgeons naturally start to look at it in both settings, where meeting the patient where they're at.
- we've effectively raised our guidance for the full year around IDOS and we continue to see that growing momentum that you'd hope for around the utilization of that.
- An important moment along that journey is the establishment of a J code, which we would expect in mid year.
Bear points
- I just want to alert the investment community that we are not at all counting on a positive outcome. It would be a very, a very formal upside if we were able to have a positive outcome on the Eidos re-implantation discussions.
- the FDA has asked us to perform some additional testing over the period of one year. So we'll now be targeting the approval of the Eidos TRIO by year end 2027.
- We expect this mixed market headwind will continue over the course of 2025 as providers continue to navigate the impacts associated with these LCDs until anniversaries later this year.